Walchandnagar Industries Limited (WIL) is one of India's oldest and most storied heavy engineering companies, established in 1908 by Walchand Hirachand and headquartered in Pune, Maharashtra. Now in its 117th year, WIL manufactures critical, high-precision, and complex engineering equipment for India's most strategic sectors — Defence, Nuclear, and Aerospace (collectively called "DNA") — alongside industrial verticals including Energy, Cement, Oil & Gas, and Steel. The company operates from its principal manufacturing complex in Walchandnagar, Maharashtra.
In the strategic sectors, WIL is pre-qualified by NPCIL, BARC, and BHAVINI for Class I nuclear components — a certification held by very few Indian private companies, built over four decades. In aerospace, the company has delivered hardware for ISRO's Chandrayaan-3, Aditya-L1, and the Gaganyaan Crew Escape System. In defence, WIL contributes to missile programmes including QRSAM, Akash-NG, and Astra. The company is in a multi-year transition from industrial engineering dependence toward DNA sector dominance, but this transition has weighed on near-term revenues and profitability.
Value Chain Position — Nuclear Segment
Raw Materials Steel, Alloys, Ti
→
Forgings & Castings
→
WIL ★ Precision Fabrication & Assembly
→
NPCIL / BARC / BHAVINI
→
Nuclear Power Plants
→
Electricity /National Grid
Nuclear Components
Calandria, moderator heat exchangers, end shields, pressurisers, distillation columns, ECCS accumulators, reactor headers, steam generators. Unique NPCIL Class I pre-qualification.
Aerospace Sub-Systems
Structural sub-assemblies for ISRO missions (Chandrayaan-3, Aditya-L1, Gaganyaan CES). Targeting SSLV privatisation participation and expanded ISRO supply contracts.
Defence Systems
Precision machined parts and assemblies for QRSAM, Akash-NG, Astra missile systems. MoU with IIT Ropar (Nov 2024) for collaborative R&D in defence/aerospace.
A2 · Capabilities + Strategy
Core Manufacturing Capabilities & Strategic Direction
🏭 Heavy Fabrication
Large-diameter pressure vessels, heat exchangers, reactors. Equipped for titanium, duplex stainless steel, and exotic alloy fabrication. Facility capable of handling critical Class I nuclear components under strict quality protocols (NPCIL/BARC codes).
⚙️ Precision Engineering
CNC machining centres for high-tolerance aerospace sub-assemblies. Dedicated aerospace manufacturing bay for ISRO projects. Certified to NADCAP standards for aerospace manufacturing processes.
🚀 Systems Integration
End-to-end project execution from design-to-delivery for nuclear and defence equipment. Dedicated project management infrastructure. IIT Ropar MoU (Nov 2024) enables access to frontier research in autonomous defence systems and space propulsion.
Strategic Priorities (FY25–FY28)
1. DNA Transition
Accelerate shift from industrial (cement, steel) to DNA revenues. Target >70% of order book from defence, nuclear, aerospace by FY27. Reduces cyclicality and elevates margin profile over time.
2. Nuclear Order Capture
Leverage SHANTI Bill (Dec 2025) and India's 100 GW nuclear target to win next-gen PHWR and SMR supply contracts. NPCIL RFP for 40–50 Bharat Small Reactors directly addressable by WIL.
3. Capex Deployment
Deploy recent capex investments to expand manufacturing throughput. Ensure plant readiness ahead of anticipated order inflows from nuclear fleet-mode programme. Aerospace bay capacity ramp-up for Gaganyaan production phase.
A3 · Market Opportunity
Why Now — TAM, Tailwinds & Positioning
Nuclear TAM — India
India targets 100 GW nuclear capacity by 2047 (vs ~8 GW today). Annual investment required: ~US$10 Bn (~₹85,000 Cr/yr). Nuclear Energy Mission: ₹200 Bn (~₹20,000 Cr) dedicated budget. Fleet-mode PHWR programme: 40–50 × 220 MW Bharat Small Reactors. WIL addresses ~₹50–200 Cr per reactor in Class I components.
Aerospace TAM — India
ISRO annual budget: ~₹13,000 Cr and growing. SSLV privatisation: ~₹1,500–2,000 Cr programme over 5 years. Gaganyaan crewed missions: multiple flights planned through 2028–2030. Private space sector growing under IN-SPACe framework. WIL already embedded in supply chain.
Defence TAM — India
India defence budget: ₹6.2 Lakh Cr in FY25. Domestic procurement target: 70% by FY28. Missile programmes (QRSAM, Akash-NG, Astra Mk2): multi-1000 Cr annual outlay. WIL contributes precision manufacturing to DRDO-led programmes. Indigenisation push = sustained order visibility.
Timeframe Assessment
Horizon
Catalyst
Expected Impact
0–12M
Q3/Q4 FY26 recovery; aerospace order announcements; nuclear contracts (3–6 months per MD)
Revenue recovery visible; order book rebuilds from ₹670 Cr toward ₹800+ Cr
India nuclear fleet buildout (10+ reactors/yr); SMR programme; private nuclear under SHANTI Bill
WIL as structural beneficiary of India's nuclear decade; potential 3–5x revenue scale
Key Structural Tailwind: The SHANTI Bill (Dec 2025) unlocks private sector participation in nuclear power for the first time in Indian history. WIL's four-decade head start in NPCIL pre-qualification creates a near-impossible-to-replicate moat for new entrants. The question is execution and financial health, not sector access.
Signed Nov 4, 2024; joint R&D in autonomous defence & space propulsion
HF Reactor Supply Order
Industrial
Chemical sector
Supply order received (contributed to stock +5% move)
Order Book Note: Order book stood at ₹938 Cr (FY24 end), declining to ~₹670 Cr as of Q3 FY26 — indicating execution outpaced new order wins. Management expects major aerospace orders in Q4 FY26 and nuclear contracts in 3–6 months. Order book rebuild is a key milestone to track.
A5 · Financials + Growth
5-Year Annual Financial Trends
Revenue (₹ Cr) + YoY Growth %
EBITDA (₹ Cr) + EBITDA Margin %
PAT (₹ Cr) — Net Profit/Loss
Order Book (₹ Cr)
Note: FY21–FY22 annual financials not available from sources accessed. Data marked as approximate where interpolated. Verify full 5-year data at screener.in/company/WALCHANNAG.
Annual Summary Table
Year
Revenue (₹ Cr)
YoY%
EBITDA (₹ Cr)
EBITDA%
PAT (₹ Cr)
Notes
FY21
~Data Unavailable
—
—
—
—
COVID year
FY22
~Data Unavailable
—
—
—
—
Recovery year
FY23
322
—
~-34.5
-10.7%
~-50 (est)
Revenue peak, deep EBITDA loss
FY24
302
-6.1%
~1.2
+0.4%
-41.83
EBITDA turned positive; PAT still loss
FY25
259
-14.3%
~-60 (est)
Negative
-86.03
Worst year; Q4 EBITDA -₹44 Cr
A6 · Regulatory Changes + Impact
Policy Tailwinds & Sector Developments
Scheme / Policy
Date
Relevance to WIL
Estimated Impact
Signal
SHANTI Bill 2025 Sustainable Harnessing & Advancement of Nuclear Energy for Transforming India
Dec 2025
Replaces 1962 Atomic Energy Act. Private sector can now build/own/operate nuclear plants. Creates demand for Class I nuclear components beyond NPCIL.
Transformational — addressable market expands 3–5x over 10+ years
POSITIVE
Nuclear Energy Mission
FY25 Budget
₹200 Bn dedicated mission; fleet-mode PHWR (40–50 × 220 MW BSR) RFP by NPCIL. WIL directly in supply chain for calandria, end shields, steam generators.
₹50–200 Cr per reactor over execution cycle; 40–50 reactors = ₹2,000–10,000 Cr addressable
POSITIVE
Defence Indigenisation Policy
Ongoing
70% domestic procurement target; positive import embargo on 509 defence items. WIL benefits as approved supplier for QRSAM, Akash-NG, Astra.
Incremental — ₹50–100 Cr/yr from defence over 3 years
POSITIVE
IN-SPACe Framework (Space)
2020 ongoing
Private sector space participation enabled. SSLV privatisation creates supply opportunity for WIL's aerospace division.
₹100–300 Cr over 5 years if SSLV supply role secured
NEUTRAL–POSITIVE
Labour Relations
FY25
Plant lockout at Walchandnagar factory disrupted production, contributing to revenue collapse in FY25. Lockout subsequently lifted.
Key risk — contributed to FY25 losses. Operations now resumed.
RISK — MONITOR
A7 · Analyst Research Data Mix
Brokerage Coverage & Consensus Themes
Research Framing Only. Analyst estimates sourced from publicly available reports. Not investment advice. All data for research tracking purposes only. Source: public analyst reports, ICICI Direct, MOFSL, YES Securities, JM Financial, MarketsMojo, Univest.
Brokerages Covering WIL
ICICI Direct (Rapid Results), MOFSL, YES Securities, JM Financial, MarketsMojo coverage. Primarily quantitative result analysis; limited formal initiating coverage noted. Analyst community watching recovery trajectory closely post FY25 loss.
Q4 FY26 Analyst Estimates
Revenue: ₹420–480 Cr (full-year FY26, not quarterly)
EBITDA Margin: 8–10%
PAT: ₹12–18 Cr (full-year FY26)
Key variable: Order book +20–25% YoY Source: public analyst reports — research framing only
Common Analyst Themes
1. Nuclear sector structural re-rating post SHANTI Bill
2. Revenue recovery trajectory (Q3 FY26 = first profitable Q)
3. Promoter pledge as key overhang
4. Order book rebuild pace vs. expectations
5. Ashish Kacholia presence = smart money validation
A8 · Balance Sheet + Cash Flows + Fraud Filter
Financial Health Assessment
Balance sheet line items sourced from web/public disclosures. Full BS available at screener.in/company/WALCHANNAG. Partial data shown — verify for completeness.
Item
FY25 (₹ Cr est.)
FY24 (₹ Cr est.)
Trend
Revenue from Operations
259
302
↓ -14.3%
PAT
-86.03
-41.83
↓ Losses widening
Market Cap
~1,488
—
₹1,835 Cr (Apr 2026)
Price/Book
4.22x
—
11% disc to peers
Altman Z-Score
2.03
—
Grey / distress zone
Promoter Pledge
49.2% of holding
—
⚠ HIGH
Implied Book Value/Share
~₹42
—
Declining as losses accumulate
Fraud Filter Checklist
⚠️
Receivable Days — WATCH
Nuclear/defence projects have long payment cycles. Receivable days elevated given revenue decline. Monitor for sharp spikes vs. revenue trends.
⚠️
Inventory Days — WATCH
WIP inventory likely elevated given execution slowdown in FY25. Inventory build diverging from revenue = flag to verify on screener.in.
🔴
CFO/PAT Ratio — FLAG
Company in net loss for 2+ years. CFO likely negative or very low vs. PAT. Verify cash conversion quality — key risk in capital-intensive business.
🔴
Promoter Pledge >20% — FLAG
49.2% of promoter holding pledged. This is a HIGH risk flag. If WIL stock falls, pledge invocation risk could cause forced selling. Largest single risk for minority shareholders.
✅
Related Party Transactions
No material RPT concerns flagged in public disclosures. Promoter-management aligned (Doshi family). Monitor annual report disclosures.
✅
Auditor Change
No auditor change flagged in last 3 years. Company files with BSE/NSE regularly. SEBI compliance certificate filed for Q4 FY26.
⚠️
Contingent Liabilities
Not quantified from available sources. Verify contingent liabilities as % of net worth in annual report — particularly any pending litigation from labour disputes or project delays.
⚠️
Altman Z-Score: 2.03
In grey zone (1.81–2.99 = distress risk). Indicates potential financial stress. Not immediately alarming but warrants monitoring of liquidity and debt servicing capacity.
A9 · P&L Deep Dive — Quarterly
Last 6 Quarters (Most Recent First)
Quarter
Revenue (₹ Cr)
QoQ%
YoY%
EBITDA (₹ Cr)
EBITDA%
PBT (₹ Cr)
Notes
Q3 FY26 Oct–Dec 2025
80.95
+56.3%
+37% YoY
~6.5 (est 8%)
~8%
+4.66
✅ First profitable Q in ~6+ quarters. Recovery confirmed.
Q2 FY26 Jul–Sep 2025
51.78
+20.4%
-23.7% YoY
Negative
—
Loss
Sequential improvement but still loss; revenue collapse vs FY25
Concall / MD Highlights (Jan 29, 2026 — Q3 FY26 Results): MD Chirag Doshi guided that Q3 FY26 return to profitability is a "recovery inflection." Company expects major aerospace orders in Q4 FY26. Nuclear contracts from NPCIL expected in 3–6 months. MD re-appointed for 3 years — signals continuity. Revenue up 37% YoY in Q3 FY26 validates operational recovery.
NDTV Profit Interview (Dec 13, 2025): Chirag Doshi on SHANTI Bill — "While private sector participation is a major structural positive, purchase orders from private players will come gradually. The immediate beneficiary of fleet-mode reactor orders is WIL through NPCIL." NPCIL and NTPC expected to issue new reactor orders in next 12–18 months.
A10 · Valuations
Own History + Peer Comparison
Traditional P/E valuation not applicable (net losses in FY24–FY25). P/S and P/B are primary valuation anchors. As earnings recover, P/E will become meaningful. All figures for research reference only.
Metric
Current
Peer Median
Position
P/E Ratio
N/A (Losses)
~30–50x (sector)
Not meaningful — await earnings recovery
P/Book
4.22x
4.74x
11% discount to peers
P/Sales
6.3x
4.3x
47% premium — rich on revenue basis despite losses
Market Cap
₹1,835 Cr
~₹930 Cr (peer median)
Premium to peers — reflects DNA re-rating optionality
EV/EBITDA
Not meaningful
—
EBITDA negative — 3Y average was ~540x (data volatility)
Altman Z-Score
2.03
—
Grey zone — financial stress monitor
Peer Comparison — Heavy Engineering / Defence / Nuclear
Company
Mkt Cap (₹ Cr)
P/E
P/B
DNA Exposure
Financial Health
BHEL (NSE: BHEL)
~75,000
~85x
~3.5x
Medium (power, defence)
Moderate
MTAR Technologies (NSE: MTARTECH) ⚡
~4,200
~55x
~7x
High (nuclear, space, defence)
Strong
MIDHANI (NSE: MIDHANI)
~5,200
~40x
~4.5x
High (defence, aerospace alloys)
Strong
Paras Defence (NSE: PDSLTD)
~1,400
~45x
~6x
High (defence electronics)
Good
Walchandnagar (WIL) ⚡
₹1,488
N/A (Loss)
4.22x
Very High (DNA pure-play)
Stressed
⚡ = On your iList watchlist. Source: public market data, web research — research framing only.
A11 · Order Book Tracker
Pipeline Visibility & Recent Wins
Current Order Book
~₹670 Cr
Q3 FY26 est. | Nuclear-heavy
Peak Order Book
₹938 Cr
FY24 end | Pre-lockout
Book-to-Bill (est.)
~2.6x
₹670 Cr / ~₹259 Cr revenue
Long-Term Contracts
2 contracts
~₹400 Cr over 25 years
Order Book Trend (₹ Cr)
Date
Client
Segment
Value / Details
Delivery
Nov 2024
IIT Ropar
Defence/R&D
MoU for joint research in autonomous defence & space propulsion
Gaganyaan Crew Escape System sub-assemblies delivered
Delivered
FY25
Chemical sector
Industrial
HF Reactor supply order (stock +5% on announcement)
FY26
Expected Q4 FY26
ISRO/Private
Aerospace
Major aerospace orders guided by MD (awaited)
TBD
Expected 3–6M
NPCIL
Nuclear
New nuclear contracts per MD guidance (post SHANTI Bill orders)
TBD
A12 · Track Record + Management Quality
Leadership, Guidance History & Capital Allocation
Chirag C. Doshi — MD & CEO
Promoter family (Doshi family); deep sector knowledge in nuclear/defence engineering. Re-appointed for 3 years on Jan 29, 2026 — signals continuity and board confidence. Regular media presence (NDTV Profit, Bloomberg). Has openly acknowledged FY25 revenue challenges and guided recovery timeline.
Promoter Background
Doshi family descendant of Walchand Hirachand legacy. 4-decade nuclear sector relationship with NPCIL/BARC. However, 49.2% pledge on promoter holding is a concern — suggests liquidity pressure or financing needs at promoter level. Low overall promoter holding (31.59%) limits alignment with minority shareholders.
Capital Allocation Track Record
Company has invested in manufacturing capex (aerospace bay, nuclear fabrication). Dividend payouts appear suspended given sustained losses. No major acquisitions or buybacks on record. Capital deployed toward plant modernisation and R&D collaboration (IIT Ropar). Bond with NPCIL maintained through consistent quality delivery.
Guidance vs. Actuals
Period
Management Signal
Actual Outcome
Assessment
FY24
EBITDA recovery anticipated
EBITDA turned positive (+0.4%); PAT still loss
Partial — directionally right
FY25
Revenue growth expected via order execution
Revenue -14.3%; Net loss doubled to ₹86 Cr
Miss — plant lockout disruption
Q3 FY26
Recovery signaled from H1 FY26
Revenue +37% YoY; PBT ₹4.66 Cr (profit)
Met — recovery confirmed
Q4 FY26
Major aerospace orders; nuclear contracts in 3–6M
Pending (Q4 FY26 results expected May 2026)
Watch
A13 · Issues + Risks
Risk Assessment Matrix
HIGH
Promoter Pledge (49.2%)
Nearly half of promoter holding is pledged. If stock declines sharply, lenders can invoke pledges leading to forced selling, further depressing the price — a reflexive negative spiral.
Mitigant: Monitor pledge % quarterly. Reduction of pledge would be highly positive. Stock above ₹150 reduces near-term risk.
HIGH
Sustained Profitability
Company lost ₹86 Cr in FY25 and ₹42 Cr in FY24. Q3 FY26 showed first profit (₹4.66 Cr PBT) — but recovery is fragile. Any new disruption could reverse this. Working capital pressures remain.
Mitigant: Order book rebuild + aerospace order wins in Q4 FY26 would provide multi-quarter revenue visibility.
HIGH
Labour / Operational Risk
FY25 plant lockout severely disrupted revenue (Q4 FY25 EBITDA: -₹44 Cr). Walchandnagar facility has history of labour relations challenges. Recurrence would damage recovery thesis.
Mitigant: Lockout lifted; operations resumed. Monitor industrial relations through annual report and news.
MED
Order Book Execution Risk
Order book declined from ₹938 Cr (FY24) to ~₹670 Cr (Q3 FY26). New order wins have not kept pace with execution. Revenue recovery depends on both executing current book AND winning new orders.
Mitigant: Nuclear fleet-mode programme and aerospace pipeline provide visibility; but order materialisation timelines can slip.
MED
Revenue Concentration Risk
Heavy dependence on government entities (NPCIL, ISRO, DRDO). Any slowdown in government capex spend or order release delays directly impacts WIL revenues and cash flows.
Mitigant: SHANTI Bill diversifies customer base over time as private nuclear players emerge.
MED
Low Promoter Holding
Promoter holding at 31.59% is low for a company of this strategic sensitivity. Public float is 67.84%, creating potential for volatility and governance concerns in high-stakes projects.
Mitigant: Doshi family has long-term track record with the company. Monitor for promoter buying or selling activity.
MED
Competition in Nuclear Components
L&T is a large-scale competitor in nuclear components. Larsen's scale, balance sheet, and NPCIL relationships could crowd out WIL in large-ticket reactor contracts (calandria, end shields) if nuclear programme accelerates rapidly.
Mitigant: WIL's Class I nuclear pre-qualification is not easily replicable. Fleet-mode volume could support both L&T and WIL simultaneously.
LOW
Altman Z-Score Distress Zone
Z-score of 2.03 places WIL in the grey zone. Not a near-term solvency threat but signals financial stress that warrants monitoring of debt levels, interest coverage, and working capital.
Mitigant: Government-linked revenue provides some payment certainty. Monitor through quarterly results and debt schedule.
LOW
Nuclear Sector Gestation
Fleet-mode PHWR orders are expected over 12–18 months but nuclear procurement is slow (NPCIL RFP extended to March 2026). Order materialisation may take longer than guidance suggests.
Mitigant: Aerospace and defence orders can bridge near-term gaps while nuclear pipeline matures.
A14 · Key Milestones / Metrics to Track
RESEARCH TRACKING MILESTONES — NOT INVESTMENT SIGNALS
Order Book
Order Book Rebuild to ₹800+ Cr
⏱ Q4 FY26 – Q1 FY27
Confirms new order wins are outpacing execution. Reversal of 18-month order book decline. Nuclear + aerospace order announcements are the catalysts.
Aerospace
Major Aerospace Order Announced (Q4 FY26)
⏱ April–May 2026
MD guided "major aerospace orders in Q4 FY26." A large ISRO or private space order would validate the aerospace thesis and contribute to order book re-rating.
Nuclear
NPCIL Fleet-Mode PHWR Supply Contract
⏱ Q1–Q2 FY27 (3–6M per MD)
First fleet-mode reactor supply order from NPCIL would be transformational for WIL's long-term revenue visibility and potentially trigger a re-rating.
Financials
Q4 FY26 Revenue ≥ ₹100 Cr + EBITDA Positive
⏱ May 2026 (Q4 FY26 results)
Q3 FY26 was ₹80.95 Cr with ₹4.66 Cr PBT. Q4 must show sequential improvement. ≥₹100 Cr with sustained EBITDA > 8% would confirm operational recovery is durable.
Governance
Promoter Pledge Reduction Below 30%
⏱ Ongoing — monitor quarterly
Current 49.2% pledge is the largest governance overhang. Any reduction would materially de-risk minority investors and potentially attract institutional buyers.
Regulatory
Private Nuclear Licensing under SHANTI Bill
⏱ FY27–FY28 (regulatory framework takes time)
First private nuclear licence under SHANTI Bill would unlock entirely new customer segment for WIL and validate the 100 GW nuclear opportunity for component suppliers.
Earnings
Full-Year FY27 PAT Positive (First Since FY23)
⏱ May 2027
Return to full-year profitability would be the clearest signal of operational and financial turnaround. Enables P/E based valuation and attracts a broader institutional investor base.
Promoter Pledge Alert: 49.2% of promoter holding (31.59% overall) is pledged. This creates a reflexive risk — any sustained share price decline could trigger lender margin calls and forced selling. This is the #1 governance risk for WIL. Ashish Kacholia reduced stake from 3.17% → 2.06% — partial smart money exit warrants attention.
⚠ All technical levels are research reference levels — not investment signals. Source: TradingView Screener MCP (live data), web research.
B0 · Stage Analysis + Setup
Wyckoff Stage, Pattern & TV TA Consensus
📊 Wyckoff Stage
Stage 2 Mark-up / Early Stage Recovery
Stock has recovered from ₹131.15 (52W low) to current ₹219.19 — a 35.5% recovery. Still significantly below 52W high of ₹277.75. Weekly MAs aligning constructively. Recovery appears to be from a base following the FY25 capitulation. Structure is tentative — not a confirmed Stage 2 yet; recovery must hold above ₹150 support zone.
🎯 Setup Type
Base / Early Pullback Recovery
Stock formed a base between ₹131–₹155 during FY25 operational stress. Q3 FY26 earnings catalyst drove a move higher. Current pattern: early recovery from deep base. No confirmed breakout above prior resistance (₹220–₹240 zone). Watching for consolidation and re-test of base before potential higher move.
Not directly extracted from screener output. Weekly TA summary = BUY with oscillator score 0.18. Implied RSI range: 45–60 (neutral-to-mildly bullish zone). Not overbought. Check live RSI on TradingView (NSE:WALCHANNAG, Weekly).
MACD (Weekly)
Weekly MA score of 0.80 suggests MACD is constructive — likely above signal line or recently crossed over. Histogram direction: improving. Daily MACD: neutral. Cross-reference live chart for confirmation.
Price vs Key MAs
CMP ₹219.19 vs 52W range ₹131.15 – ₹277.75 52W range position: ~40% from low, ~61% below high
MA alignment: weekly MAs turning constructive (score 0.80)
Price above short/medium MAs on weekly timeframe.
~40% recovery from 52W low toward 52W high
B2 · Key Levels
Research Reference Price Levels — Not Investment Signals
All levels are research reference levels only. Source: 52W data (web), swing levels (chart analysis).
Price Level Map — NSE: WALCHANNAG
Support 2Support 1CMPResistance 1Resistance 252W High
₹131₹150–155₹219.19₹200–210₹240–250₹277.75
Level Type
Price (₹)
Basis
Significance
Strong Support 2
₹131.15
52W Low
Major base — capitulation low during FY25 operational crisis
Support 1
₹150–155
Base consolidation zone
Demand zone built during FY25 distress; prior resistance turned support
CMP
₹219.19
Current price
Mid-recovery zone; building above base
Resistance 1
₹200–210
Prior swing high / round number
First meaningful supply zone; break above = confirms recovery
Resistance 2
₹240–250
Pre-FY25 base / prior pivot
Key level for full recovery thesis; break above attracts momentum buyers
52W High
₹277.75
52W High
Full recovery back to prior high — requires sustained operational turnaround
WALCHANNAG ranks #2 out of 4 in peer TA comparison — fractionally behind BHEL but ahead of TITAGARH and KILITCH. Weekly MA alignment (score 0.80) is the primary positive signal. WALCHANNAG is technically in better shape than most sector peers on the weekly timeframe.
Relative Strength vs Nifty 500
52W: stock at ₹219.19 vs 52W low ₹131.15 = +35.5% recovery. Nifty 500 has broadly recovered from Apr 2025 lows. RS vs Nifty 500 over 1Y: underperforming (52W high ₹277.75 = -36% from high vs current). RS trend: improving in 3M as Q3 FY26 profit recovery anchors sentiment. Full RS leadership requires consistent outperformance above ₹220.
Long-Term Trend Quality
Weekly structure shows wide/loose consolidation during FY25 operational distress. Q3 FY26 results stabilised the base. Trend quality improving but not yet "tight" enough for high-confidence momentum setup. Prefer to see 2–3 quarters of revenue growth + EBITDA expansion before trend quality confirms.
Captured from TradingView Desktop Dark Mode layout · Weekly timeframe · Apr 25, 2026
Source: TradingView Desktop — NSE:WALCHANNAG · Weekly · Research Reference Only
📊 TV Fundamentals Layout
IN Analytics + Fundamentals Panel — TradingView Desktop Capture
Captured from TradingView Desktop FUNDAMENTALS layout · IN Analytics, Stage/RS/Momentum/MA panels · Apr 25, 2026
Source: TradingView Desktop — FUNDAMENTALS layout · Research Reference Only
⚠️ IMPORTANT DISCLAIMER
This document is a research and educational output only, generated by the Primaegis Research Investment Analysis Pipeline.
Neither Primaegis Research nor any contributor to this report is a SEBI registered investment advisor or research analyst.
Nothing in this report constitutes investment advice, a research recommendation, or a solicitation to buy, sell, or hold any security, fund, or financial instrument under SEBI (Research Analyst) Regulations, 2014 or any other applicable law.
All financial data is sourced from publicly available disclosures (Screener.in, BSE, NSE, company website, public analyst reports, news sources). All technical levels are research reference levels for tracking only. Analyst estimates are from public reports — research framing only, not investment recommendations.
Always conduct your own due diligence and consult a SEBI registered investment advisor before making any financial decision.
Generated: April 25, 2026 | Primaegis Research · Investment Analysis Pipeline · Not for distribution.
